Table 2 Characteristics of the studies included in the meta-analysis
Study | Group | Cases | Average age (ys) | Male rate (%) | Tumor size (cm) | No. of tumor≥2 (%) | Cirrhosis (%) | Child-Pugh (%,A/B) | Hepatic virus | Therapy |
|---|---|---|---|---|---|---|---|---|---|---|
Kubo S (2002) | Interferon | 15 | 61.9 | 100.0 | 2.5 | 0 | 46.7 | 73.3/26.7 | HCV | Surgical resection |
Placebo | 15 | 60.0 | 100.0 | 2.6 | 0 | 52.2 | 80.0/20.0 | |||
Shiratori Y (2003) | Interferon | 49 | 61.0 | 71.4 | 2.2 | 34.7 | 100.0 | -- | HCV | Surgical resection |
Placebo | 25 | 63.0 | 68.0 | 2.3 | 36.0 | 100.0 | -- | |||
Lin SM (2004) | Interferon | 20 | 61.5 | 80.0 | 2.2 | 15.0 | 90.0 | 85.0/15.0 | HBV/ HCV | TACE |
Placebo | 10 | 59.0 | 70.0 | 2.5 | 20.0 | 100.0 | 90.0/10.0 | |||
Piao CY (2005) | Interferon | 30 | 59 | 76.7 | 2.3 | 23.3 | 13.0 | 60.0/36.7 | HBV/ HCV | Ablation/TACE/surgical resection |
Placebo | 40 | 58 | 72.5 | 2.5 | 17.5 | 23.0 | 55.0/42.5 | |||
Mazzaferro V (2006) | Interferon | 76 | 65.0 | 80.3 | 3.4 | 22.4 | 94.0 | 92.1/7.9 | HCV | Surgical resection |
Placebo | 74 | 67.0 | 68.9 | 3.2 | 25.7 | 88.0 | 94.6/5.4 | |||
Sun HC (2006) | Interferon | 118 | 52.2 | 89.8 | 4.3 | 13.6 | 83.1 | -- | HBV | Surgical resection |
Placebo | 118 | 50.4 | 86.4 | 4.9 | 12.7 | 88.1 | -- | |||
Lo CM (2007) | Interferon | 40 | 49.0 | 77.5 | 5.5 | 17.5 | 47.5 | -- | HBV/ HCV | Surgical resection |
Placebo | 40 | 54.0 | 85.0 | 5.7 | 27.5 | 47.5 | -- | |||
Li M (2009) | Interferon | 108 | 50.3 | 71.3 | 4.9 | 54.6 | 100.0 | 90.7/9.3 | HBV | TACE |
Placebo | 108 | 49.2 | 68.5 | 4.8 | 54.6 | 100.0 | 91.7/8.3 | |||
Li N (2010) | Interferon | 43 | 53.2 | 72.5 | 3.2 | 37.2 | 88.0 | 85.0/15.0 | HBV | TACE |
Placebo | 36 | 51.2 | 71.3 | 3.4 | 37.2 | 88.0 | 85.0/15.0 | |||
Ishikawa (2012) | Interferon | 29 | 59.0 | 83.2 | 2.3 | 13.5 | 100.0 | -- | HCV | TACE |
| Â | Placebo | 25 | 58.7 | 81.2 | 2.5 | 17.4 | 100.0 | -- | Â | Â |